HOME >> BIOLOGY >> NEWS
Loyola begins study on blood substitute in trauma patients at the scene of injury

MAYWOOD, Ill. Loyola University Health System begins today the national clinical trial using PolyHeme®, an investigational oxygen-carrying blood substitute designed to increase survival of critically injured and bleeding trauma patients at the scene of injury. Loyola has been involved in extensive public education, staff education and paramedic training since its Institutional Review Board for the Protection of Human Research Subjects (IRB) approved the clinical trial in May. Loyola is one of 20-25 Level I trauma centers which will participate in the trial nationwide and the only one in Illinois.

"If the blood substitute works the way we hope it will, it could be the first major advance since the introduction of saline, or salt water, to replace volume after blood loss, around the time of World War I," said Dr. Richard L. Gamelli, principal investigator, chair of the Department of Surgery and professor of trauma surgery, Loyola University Chicago Stritch School of Medicine.

Currently, patients can only receive blood in a hospital and that means a trauma victim may need to wait up to an hour for a transfusion following transport to the hospital and being typed and cross-matched.

"Saline, the current standard of care, helps us restore a patient's blood pressure but does not deliver oxygen, a critical nutrient to prevent organ damage in the brain, heart, lungs, liver and kidneys," Gamelli explained.

"Carrying blood in an ambulance isn't practical because it needs to be refrigerated, has a short shelf life and needs to be typed and cross-matched to the specific patient. In contrast, the blood substitute carries oxygen, has a long shelf life and is compatible with all blood types," said Gamelli, who also is chief of Loyola's Burn Center and director of Loyola's Burn and Shock Trauma Institute.

In order to receive approval for the field component of this clinical trial, U.S. Food and Drug Administration regulations
'"/>

Contact: Stephen Davidow
sdavidow@lumc.edu
708-216-8232
Loyola University Health System
2-Nov-2004


Page: 1 2 3

Related biology news :

1. Loyola prof. aids in discovery of first case of insect transmission of Chagas parasite in Louisiana
2. Loyola researchers discover congestive heart failure biological marker
3. Loyola sets another world record for smallest baby at 8.6 ounces
4. Study begins to reveal clues to the cause and progression of sepsis
5. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
6. Food safety begins as vegetables grow
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. National Academies advisory: Two-day stem cell symposium begins November 7
9. Stevens CSW begins list of 100 Greatest Science Books
10. With $10M in grants, UMaine begins forest biorefining research
11. Finding life on Mars and outer space begins by examining Earths inner space

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
Breaking Biology Technology:
Cached News: